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Abstract
Background: There is limited knowledge of serotypes that cause non-bacteremic pneumococcal pneumonia (NBP).
Here we report serotypes, their associated disease potential and coverage of pneumococcal conjugate vaccines
(PCV) in adults with NBP and compare these to bacteremic pneumonia (BP).
Methods: Adults with pneumonia and Streptococcus pneumoniae isolated from the lower respiratory tract or blood
were included 1 year in a population-based design in Denmark. Pneumonia was defined as a new infiltrate on chest
radiograph in combination with clinical symptoms or elevated white blood count or plasma C-reactive protein. All
isolates were serotyped using type-specific pneumococcal rabbit antisera. All values are medians with interquartile
ranges.
Results: There were 272 cases of NBP and 192 cases of BP. Ninety-nine percent were hospitalized. NBP and BP
cases were of comparable age and sex but NBP cases had more respiratory symptoms and less severe disease
compared to BP cases. In total, 46 different serotypes were identified. Among NBP cases, 5 serotypes accounted for
nearly a third of isolates. PCV10 and -13 types covered 17% (95% confidence interval (CI): 11-23%) and 34% (95%
CI: 25-43%) of NBP isolates, respectively. In contrast, the five most frequent serotypes accounted for two-thirds of
BP isolates. PCV10 and -13 types covered 39% (95% CI: 30-48%) and 64% (95% CI: 48-79) of BP isolates,
respectively. More severe NBP disease was associated with infection with invasive serotypes while there was an
inverse relationship for BP.
Conclusions: Only a third of cases of adult non-bacteremic pneumococcal pneumonia would potentially be
preventable with the use of PCV13 and just one sixth of cases with the use of PCV10 indicating that PCVs with
increased valency are needed to increase vaccine coverage for NBP in adults. PCV13 could potentially prevent two-
thirds of adult bacteremic pneumococcal pneumonia.
Citation: Benfield T, Skovgaard M, Schønheyder HC, Knudsen JD, Bangsborg J, et al. (2013) Serotype Distribution in Non-Bacteremic Pneumococcal
Pneumonia: Association with Disease Severity and Implications for Pneumococcal Conjugate Vaccines. PLoS ONE 8(8): e72743. doi:10.1371/
journal.pone.0072743
Editor: Bernard Beall, Centers for Disease Control & Prevention, United States of America
Received February 28, 2013; Accepted July 12, 2013; Published August 23, 2013
Copyright: © 2013 Benfield et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by an unrestricted, investigator-initiated grant from Pfizer. The authors conceived the study and the study design was
developed and agreed to by the authors without any input from the funding body. The study concept and design was peer reviewed prior to award of the
grant from the funding body. The funding body was not involved in and, had no influence over, study design, data collection, data analyses, interpretation of
results, report writing or in the decision to submit the paper for publication. All study data are held solely by the authors.
Competing interests: The PCV13 vaccine described in this study is produced by Pfizer. There are no further patents, products in development or
marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in
the guide for authors.
* E-mail: tlb@dadlnet.dk
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e72743
Introduction
Pneumonia is a leading cause of morbidity and mortality
globally. Annual rates of hospitalization for community-acquired
pneumonia (CAP) range from 2 to 4 per 1000 adult population
in Europe [1,2]. More than half of pneumonia cases requiring
hospitalization are believed to be caused by infection with
Streptococcus pneumoniae [3]. Use of pneumococcal
conjugate vaccines (PCV) for children has significantly reduced
their rates of bacteremic and perhaps also non-bacteremic
pneumococcal disease [4–6] but the efficacy of PCV for
immunocompetent adults remains unknown. Data from a
predominantly HIV-infected population, however, indicated that
PCV7 was highly efficacious in preventing adults from
reinfection with S. pneumoniae but the study did not distinguish
between bacteremic and non-bacteremic pneumonia [7].
Protection conferred by the 23-valent polysaccharide vaccine
(PPV23) is controversial for bacteremic pneumonia and
doubtful for non-bacteremic pneumonia [8]. Further, the
specificity of the vaccine is serotype dependent and therefore
the protection it may confer is influenced by geographical and
temporal changes in serotype distribution.
The pneumococcus is encapsulated by polysaccharide that
protects it from host immune responses and is an important
virulence factor. Variation of the capsule results in more than
90 different serotypes [9]. Poor outcome from pneumococcal
disease is related to serotypes with high carriage rates, low
invasiveness and heavy encapsulation [10–12]. While there is
an abundance of data relating to invasive pneumococcal
serotype distribution [13,14] there are very few studies that
report serotype distribution of non-bacteremic pneumococcal
pneumonia [15,16].
The current study was undertaken in order to establish the
distribution of pneumococcal serotypes that cause non-
bacteremic pneumonia (NBP), their association with disease
severity and to compare them to cases of bacteremic
pneumococcal pneumonia (BP). A secondary aim was to
establish the potential coverage in Denmark of currently




From January through December 2011 consecutive first
episodes of pneumococcal pneumonia in patients over the age
of 15 years with a pneumococcal isolate from the lower
respiratory tract and/or blood diagnosed at one of 15 hospitals
served by one of three Departments of Clinical Microbiology at
Aalborg, Herlev or Hvidovre Hospital, respectively, were
included. The entire catchment population was approximately
1.9 million adults (16 years or older), serving patients from the
15 hospitals and over 1000 general practitioners. The National
Health Board (record no. 7-604-04-2/332) and the Danish Data
Protection Agency (record no. 2011-41-6426) approved this
study. Informed consent is not required by Danish legislation
for register-based studies.
Clinical, demographic, laboratory and microbiological data
were abstracted from patient charts.
Demographic data included age, sex, smoking, alcohol use,
and pneumococcal vaccination status. We ascertained the
presence of acute respiratory symptoms (dyspnoea, cough,
sputum production or chest pain) and recorded chest
radiograph findings. Plasma C-reactive protein level (CRP),
white blood cell count (WBC), body temperature, mean arterial
blood pressure (MAP), peripheral oxygen saturation (SAT), and
two disease severity scores, the CURB-65 score [17] and the
Pitt score [18] within 24 hours of pneumonia was noted.
Nosocomial infection was defined as an infection occurring
more than 48 hours after admission to hospital [19].
Charlson’s comorbidity index (CCI) scores were calculated
for each patient. The CCI score is a weighted index that
includes 19 different disease categories and takes into account
the number and the seriousness of comorbid disease [20,21].
Data on each patient’s complete hospitalization history of co-
existing diseases was obtained from The Danish National
Registry of Patients (DNRP) using linkage by unique civil
registration numbers. The DNRP includes all patient
admissions to Danish hospitals since 1977 and all hospital
outpatient visits since 1995 [22]. Three comorbidity levels were
defined: low (score of 0), medium (1,2), and high (≥3).
Microbiological data included the results for all sputum
Gram-stains, cultures from the lower airways, blood cultures,
and pleural fluid cultures as obtained at the managing
physician’s discretion (e.g. when infection was suspected). The
methods for performing each of these tests were those in place
at the participating institutions, however, at all departments
sputum was processed for culture only if it contained a
significant number of leukocytes (>25 per low power field) with
or without columnar epithelial cells, and/or no or few squamous
epithelial cells (<10 per low power field) [23]. Blood samples
were cultured for at least five days before declared negative. A
sample was only regarded as positive for pneumococci if a
culture isolate was available. Identification of S. pneumoniae
was done with standard methods including Gram stain,
detection of capsular antigen by latex agglutination as well as
optochin test or bile solubility test [24]. All isolates were
serotyped by pneumotest latex and Quellung reaction using
type-specific pneumococcal rabbit-antisera at Statens Serum
Institut (SSI) as previously described (SSI-Diagnostica,
Copenhagen, Denmark) [24,25].
Definition of pneumonia
We defined pneumonia as a new infiltrate on a chest
radiograph together with two or more clinical symptoms
(dyspnoea, cough, sputum production, chest pain, and/or body
temperature > 38°C or < 36.1°C) and/or WBC > 109 cells/L) or
plasma CRP > 30 mg/L) [26]. Severe pneumonia was defined
as pneumonia with a CURB-65 score ≥ 2 [17].
Statistics
All values are median and interquartile range or percentages
with 95% confidence interval (CI) unless otherwise specified.
Differences in continuous variables were tested by the Mann-
Whitney test. A difference in categorical data was tested by
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Fisher’s exact test or χ2 statistics, as appropriate. We used
logistic regression to analyze factors associated with infection
with a PCV serotype. Data was analyzed using IBM SPSS
Statistics (version 20; IBM, Armonk, New York, USA).
Results
Subjects
During 2011, 1101 consecutive individual subjects suspected
of pneumonia and with a pneumococcal culture isolate were
included in the study. Six hundred and twenty-nine were
excluded because they did not fulfill the criteria for pneumonia
or bacteremia; 385 did not have a chest radiographic infiltrate,
211 had not had a chest radiograph performed; and 43 could
not be cultured at SSI. Of the 472 included individuals with a
radiographic infiltrate, 280 had S. pneumoniae isolated from an
airway sample and clinical and laboratory criteria compatible
with bacterial pneumonia (NBP). Eight had a different etiology
by blood culture and were excluded (Staphylococcus aureus
(3), S. epidermidis (1), Haemophilus influenzae (1), non-
hemolytic streptococcus (1), and Fusobacterium sp. (1)). Of the
remaining 272, 199 (73%) had a negative blood culture and 73
did not have a blood culture. Patients without a blood culture
were comparable with regard to sex and comorbidity but had
lower temperature (P=0.0001), WBC (P=0.04), plasma CRP
(P=0.0001), Pitt score (P=0.001), CURB-65 score (P=0.04) and
higher MAP (P=0.002) compared to patients with a blood
culture. One hundred and ninety-two had an infiltrate and S.
pneumoniae isolated from blood (BP). For NBP, 248 of 272
(91%) cases were community-acquired and 181 of 192 (94%)
BP cases were community-acquired. Four hundred and sixty-
five (98.5%) of all included patients were hospitalized.
Individuals with NBP were of comparable age, were more
often men, had more respiratory symptoms, lower WBC, lower
plasma CRP, lower body temperature, lower severity scores
and more comorbidity compared to individuals with BP.
Comorbidity among NBP was predominantly chronic pulmonary
disease. There were no significant differences between groups
with regard to smoking, alcohol use, travel history or
pneumococcal immunization. Characteristics of study subjects
are given in table 1.
Serotypes
In total, 46 different pneumococcal serotypes were identified.
In NBP, 5 of 43 different serotypes (3, 11A, 19A, 6C, and 7F)
accounted for nearly a third of isolates. Among BP cases, 5 of
34 serotypes accounted for two-thirds of isolates (1, 7F, 3, 8
and 19A). The serotype distribution is shown in table 2 and
Figure 1.
Pneumococcal conjugate vaccine coverage
The serotypes included in current pneumococcal protein
conjugate vaccine formulations are: serotypes 1, 4, 5, 6B, 7F,
9V, 14, 18C, 19F, 23F in the ten-valent pneumococcal
Haemophilus influenzae protein D conjugate vaccine (PCV10;
GlaxoSmithKline) and serotypes 3, 6A, and 19A are
additionally included in the 13-valent pneumococcal conjugate






pneumonia, N=192 P value
Age, years 68 (58-78) 68 (56-80) 0.82
Male 172 (63.2%) 107 (55.7%) 0.12
Respiratory symptoms    
0 3 (1%) 8 (4%)  
1 6 (2%) 10 (5%)  
2 22 (8%) 29 (15%)  
≥3 128 (47%) 51 (27%)  
Unknown 113 (42%) 94 (50%) 0.0001
Blood white blood count,
109/L
14.3 (10.9-18.8) 16.9 (12.1-22.0) 0.001
Plasma C-reactive
protein, mg/L
163 (68-249) 324 (218-406) 0.0001
Temperature,°C 38.0 (37-38.8) 38.6 (37.5-39.2) 0.0001
Mean arterial pressure,
mmHg
88 (73-99) 79 (70-97) 0.009
Peripheral oxygen
saturation, %
92 (88-96) 93 (89-95) 0.71
CURB-65 score 1 (1-2) 2 (1-3) 0.003
Pitt score 0 (0-2) 1 (0-2) 0.014
Charlson Comorbidity
Index score
   
Low (0) 74 (27%) 78 (40%)  
Medium (1,2) 103 (38%) 57 (30%)  
High (≥3) 95 (35%) 57 (30%) 0.009
Median score (IQR) 2 (0-3) 1 (0-3) 0.06
Chronic pulmonary
disease
120 (44%) 38 (20%) 0.0001
Cerebrovascular disease 53 (20%) 23 (12%) 0.04
Chronic heart disease 40 (15%) 27 (14%) 0.85
Diabetes 29 (11%) 29 (15%) 0.15
HIV 2 (0.7%) 2 (1.0%) 0.73
Liver disease 12 (4%) 8 (4%) 0.89
Malignancy 49 (18%) 42 (22%) 0.30
Smoking    
Never 20 (7%) 30 (16%)  
Former 79 (30%) 50 (27%)  
Current 151 (56%) 93 (49%)  
Unknown 19 (7%) 15 (8%) 0.03
Alcohol use    
No 87 (32%) 76 (40%)  
Moderate 90 (33%) 50 (27%)  
High 61 (23%) 32 (17%)  
Unknown 32 (12%) 30 (16%) 0.08
Travel history    
No 139 (51%) 90 (47%)  
Yes 8 (3%) 6 (3%)  
Unknown 125 (46%) 96 (50%) 0.81
Pneumococcal
immunization
   
No 81 (30%) 68 (35%)  
Yes 1 (0.3%) 1 (0.5%)  
Unknown 190 (70%) 123 (64%) 0.33
Pneumococcal Serotypes in Adult Pneumonia
PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e72743
vaccine (PCV13; Pfizer). PPV23 includes 1, 2, 3, 4, 5, 6B, 7F,
8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20,
22F, 23F and 33F. PCV10 and -13 covered 16% (95%
confidence interval (CI): 11-21%) and 34% (95% CI: 25-43%)
of NBP isolates, respectively. PCV10 and -13 covered 40%
(95% CI: 32-48%) and 59% (95% CI: 48-70%) of BP isolates,
respectively. PPV23 covered 57% (95% CI: 48-66%) of NBP
and 87% (95% CI: 74-100%) of BP cases. The difference in
coverage between NBP and BP cases was statistically
significant for PCV10 (P=0.0001), PCV13 (P=0.0001) and
PPV23 (P=0.0001).
In order to identify possible clinical correlates associated with
infection caused by a vaccine serotype, we performed
multivariate logistic regression analysis, Infection with a PCV10
or a PCV13 vaccine serotype was more likely for bacteremic
cases and cases with higher plasma CRP values. Infection with
PCV10 vaccine types was less likely with increasing CCI score
while this was not the case for PCV13 vaccine types (Table 3).
Serotype and disease severity
Highly invasive serotypes are defined as 1, 5, and 7F
[12,27]. Serotype 5 was, however, not represented in our
population. Fourteen of 272 (5%) cases of NBP were caused
by invasive serotypes compared to 63 of 192 (33%) of BP
cases (P=0.0001). Invasiveness did not correlate with age
group for NBP cases (P=0.73) but there were a higher
proportion of invasive cases in the youngest age group with
bacteremic pneumonia (P=0.001, table 4). For NBP, invasive
serotypes were associated with disease severity; individuals
with Pitt score > 3 were more often infected with an invasive
serotype (5 of 31 (16%) vs. 8 of 230 (3%), P=0.01) compared
to Pitt score ≤ 3. Similarly, there was a trend towards an
association between invasive serotypes and higher CURB-65
score; individuals with CURB-65 > 3 were more often infected
with invasive serotypes (5 of 54 (9%) vs. 7 of 204 (3%),
P=0.07) compared to CURB-65 ≤ 2. Comorbidity was not
associated with invasive serotypesfor NBP (P=0.87). In
contrast, for BP a high Pitt or CURB-65 score was associated
with a non-invasive serotype; Pitt score > 3: 4 of 28 (14%) vs.
Pitt score ≤ 3: 59 of 163 (36%), P=0.02; and CURB-65 score >
2: 61 of 188 (20%) vs. CURB-65 ≤ 2: 50 of 132 (38%), P=0.02.
Similarly, there was an inverse relationship between CCI score
and serotype invasiveness: 37 of 78 (48%) episodes in patients
with low CCI; 18 of 57 (32%) and 8 of 57 (14%) with high CCI
were caused by invasive serotypes (P=0.001).
Based on previously observed specific serotype associations
with risk of mortality in invasive pneumococcal disease [10],
serotypes were predefined as high-risk: 3, 10A, 11A, 15B, 16F,
17F, 19F, 31, and 35F; moderate-risk: 6A, 6B, 9N, 12F, 14,
18C, 19A, 20, 23A, 23F, and 24F; and low-risk: 1, 4, 5, 7F, 8,
9V, 22F, 33F and 38 [10]. For NBP, there were no associations
between serotype risk group and age (P=0.81), CCI score
(P=0.98), CURB-65(P=0.32) or Pitt score (P=0.58).
Table 1 (continued).
All values are median and interquartile range or frequency with percentage.






3** 28 (10.3) 23 (12.0)
11A 21 (7.7) 2 (1.0)
19A** 18 (6.6) 13 (6.8)
6C 13 (4.8) 5 (2.6)
23A 12 (4.4) 3 (1.6)
NT 12 (4.4) 0
23B 11 (4.0) 0
35F 11 (4.0) 3 (1.6)
7F* 9 (3.3) 24 (12.5)
16F 9 (3.3) 2 (1.1)
22F 9 (3.3) 7 (3.6)
19F* 8 (2.9) 1 (0.5)
35B 8 (2.9) 1 (0.5)
9N 7 (2.6) 12 (6.2)
33F 7 (2.6) 4 (2.1)
15A 6 (2.2) 2 (1.0)
15C 6 (2.2) 1 (0.5)
1* 5 (1.8) 39 (20.3)
6B* 5 (1.8) 1 (0.5)
8 5 (1.8) 16 (8.3)
23F* 5 (1.8) 0
4* 4 (1.5) 5 (2.6)
10B 4 (1.5) 0
15B 4 (1.5) 1 (0.5)
20 4 (1.5) 1 (0.5)
12F 3 (1.1) 8 (4.2)
14* 3 (1.1) 2 (1.0)
18C* 3 (1.1) 1 (0.5)
21 3 (1.1) 0
24F 3 (1.1) 1 (0.5)
31 3 (1.1) 1 (0.5)
37 3 (1.1) 0
38 3 (1.1) 1 (0.5)
9V* 2 (0.7) 3 (1.6)
10A 2 (0.7) 2 (1.0)
11B 2 (0.7) 0
17F 2 (0.7) 2 (1.0)
35A 2 (0.7) 0
6A** 1 (0.4) 2 (1.0)
15F 1 (0.4) 0
19B 1 (0.4) 0
28F 1 (0.4) 0
32F 1 (0.4) 0
34 1 (0.4)  
35C 1 (0.4) 0
17A 0 1 (0.5)
18B 0 1 (0.5)
18F 0 1 (0.5)
*. PCV10 & 13
**. PCV13 only
NT: non-typeable
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Figure 1.  Serotype distribution for non-bacteremic (top panel) and bacteremic pneumococcal pneumonia (lower
panel).  Serotypes are listed starting with the non-typeable (NT), followed by serotypes in the pneumococcal conjugate vaccine
(PCV)-10 and PCV-13, and then the remaining serotypes. Light gray bars represent serotypes included in the 23-valent
pneumococcal polysaccharide vaccine.
doi: 10.1371/journal.pone.0072743.g001
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For BP cases there was no association with age group
(P=0.19) but there was a positive association between serotype
risk group and comorbidity: 9 of 78 (12%) with low CCI; 11 of
57 (19%) with medium CCI; and 17 of 57 (30%) with high CCI
were infected with a high-risk serotype compared to 50 of 77
(64%) with low CCI; 27 of 57 (47%); and 22 of 57 (39%) with
high CCI being infected with a low risk serotype (P=0.02). High-
risk serotypes were more frequent with disease severity: 27 of
163 (17%) with low Pitt score and 9 of 28 (32%) with high Pitt
score were infected with a high-risk serotype compared to 91 of
163 (56%) and 8 of 28 29%) with a moderate or low risk
serotype (P=0.02).
Discussion
In this study, we show that the serotype distribution of non-
bacteremic and bacteremic pneumococcal pneumonia differ
substantially. Further, we show that PCV coverage would be
Table 3. Factors associated with infection with a
pneumococcal conjugate vaccine serotype.
 Adjusted* OR (95% CI)P value
PCV10 serotype   
Bacteremia   
No 1.0  
Yes 2.72 (1.51-4.90) 0.001
Plasma C-reactive protein, per mg/L
increment
1.003 (1.001-1.005) 0.003
Charlson Comorbidity Index score   
Low (0) 1.0  
Medium (1,2) 0.66 (0.33-1.34) 0.25
High (≥3) 0.45 (0.20-0.98) 0.04
PCV13 serotype   
Bacteremia   
No 1.0  
Yes 1.88 (1.13-3.13) 0.02
Plasma C-reactive protein, per mg/L
increment
1.004 (1.002-1.005) 0.0001
OR: odds ratio; CI: confidence interval; PCV: pneumococcal conjugate vaccine
*. Variables included in the model: age, sex, CURB-65, Pitt score, temperature,
mean arterial blood pressure, peripheral oxygen saturation, white blood cell count,
C-reactive protein and chronic pulmonary disease.
Table 4. Age distribution and serotype invasiveness.











16-49 2 (14%) 31 (12%) 23 (37%) 14 (11%)
50-64 3 (22%) 67 (26%) 14 (22%) 32 (25%)
65-74 6 (43%) 70 (27%) 11 (17%) 31 (24%)
75-84 2 (14%) 65 (25%) 8 (13%) 30 (23%)
85+ 1 (7%) 25 (10%) 7 (11%) 22 (17%)
Invasive serotypes: 1 and 7F
low for non-bacteremic pneumococcal pneumonia and
acceptable for bacteremic pneumococcal pneumonia.
Preliminary findings from the on-going Dutch randomized
clinical trial designed to evaluate the efficacy of PCV13 against
adult community-acquired pneumonia are anticipated in 2014
[28]. In their trial design they have estimated a PCV13
coverage rate that is 10-15% higher for IPD than our study
suggesting that the findings from The Netherlands may have to
be adjusted to country-specific coverage rates.
Only two other studies have reported on the serotype
distribution in non-bacteremic pneumococcal pneumonia
[15,16]. The two studies and ours each applied slightly different
definitions of pneumonia and determined serotypes using
different methodology. Although our study applied the strictest
definition of pneumonia, we believe some comparisons can be
made. Similar to us, Domenech et al. showed a wider diversity
of serotypes in non-bacteremic than in bacteremic cases. The
distribution of serotypes between Denmark and Spain differed;
while two (3 and 11A) of the 3 most frequent serotypes were
similar just 4 (19A and 23A additionally) serotypes among the
10 most frequent were shared. A large proportion of our
patients had chronic obstructive lung disease. The distribution
of serotypes showed a similar pattern when compared to the
Spanish patients with chronic obstructive lung disease, i.e. 3
and 11A were the most frequent serotypes and 4 of the top 10
most frequent were similar (19A and 6C additionally) [15].
Bewick et al. did not clearly distinguish between non-
bacteremic and bacteremic cases, thus, making comparisons
between the studies difficult. Regardless, looking at the top 10
serotypes, only 4 were similar across studies. This clearly
implies that there is geographical variation in the serotype
distribution of non-bacteremic pneumonia similar to the known
geographical variation of bacteremic pneumococcal disease.
Part of the differences in distribution may be caused by
antibiotic selection of specific serotypes dependent on the
different rates of S. pneumoniae resistance between serotypes
[29]. Interestingly, 11A and 23A were common non-bacteremic
serotypes in Denmark and Spain but neither serotype was
detected in England. So while the addition of these two
serotypes to current PCVs would increase the coverage by
10% in some countries it would add nothing in other countries.
Serotypes differ in their age distribution and studies suggest
that PCV serotypes are more prevalent in the elderly adults
compared to non-elderly adults [12,13]. Thus, it is possible that
adult age groups may benefit differentially from PCVs. This
was suggested by results from Bewick et al that showed an
association between PCV serotypes and age in pneumococcal
pneumonia [16]. However, we were unable to confirm any
association between age and vaccine serotypes for neither
PCV10 nor PCV13. We did, however, show that younger
individuals were more likely to be infected with an invasive
serotype suggesting that younger, and presumably healthier,
individuals are resistant to the less invasive or opportunistic
serotypes.
Comorbidity has been suggested to increase susceptibility to
less invasive serotypes also known as opportunistic serotypes
[12]. Higher comorbidity burden was associated with a reduced
likelihood of infection with a PCV10 serotypes but not with a
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PCV13 serotype. This appears to be explained by the fact that
PCV13 includes three additional serotypes that are considered
as less invasive and that are prevalent among cases of non-
bacteremic pneumonia.
Serotype invasiveness affected disease severity differentially
for non-bacteremic and bacteremic pneumococcal pneumonia.
Infection with invasive serotypes in non-bacteremic cases lead
to more severe disease as assessed by both pneumonia and
sepsis severity scores. In contrast, bacteremic cases had lower
indices of disease severity associated with invasive serotypes.
Comorbidity did not account for this in non-bacteremic cases
since there was no association with CCI score and serotype
invasiveness whereas there was an inverse relationship
between CCI score and serotype invasiveness for bacteremic
pneumonia. Serotypes associated with high mortality did not
affect disease severity in non-bacteremic pneumonia.
Individuals with bacteremic pneumonia with low comorbidity
burden more often were infected by high-risk serotypes and
conversely. This may suggest that individuals with comorbidity
are more susceptible to infection with less virulent serotypes.
Disease severity of bacteremic pneumonia was higher for
individuals infected with high-risk serotypes compared to low-
risk serotypes.
The strength of this study is the population-based design and
careful ascertainment of pneumonia. There are several
potential limitations of our study. Blood culture was only
performed in three-quarter of patients with NBP. However,
when we excluded patients without blood culture from the
analysis the serotype coverage rate remained low (29%). We
did not have information on pre-hospital antibiotic use.
Potentially, resistant serotypes could be differentially selected
among patients prescribed antibiotics prior to being admitted to
hospital. Antibiotic resistance among S. pneumoniae is low in
Denmark. Of 901 isolates tested in the DANMAP program less
than 5% were resistant to penicillins or macrolides [30]. The 43
penicillin non-susceptible S. pneumoniae in 2011 belonged to
10 different serotypes, and the most commonly found
serotypes were type 19A (46.5%), 15A (16.3%) and 6C (9.3%).
Similarly, the 44 macrolide resistant S. pneumoniae from 2011
belonged to 11 different serotypes and the most commonly
found serotypes were type 19A (36.4%), 15A (20.5%) and 6C
(15.9%). This would suggest that, although pre-hospital
antibiotics could select for specific serotypes, the bias would be
very low. More patients with NBP had chronic obstructive lung
disease compared to patients with BP. We speculate that this
may reflect a lower threshold for investigation and sputum
sampling of patients with known chronic lung disease.
In conclusion, serotype diversity was greater in NBP than BP
cases and more likely to be caused by a less invasive
serotype. Thus, the potential coverage of currently licensed
PCVs was low, and, therefore, a vaccine constructed to
prevent pneumococcal pneumonia in adults should include
more serotypes to offer sufficient protection. However, a proper
controlled clinical trial is required to assess the efficacy of
PCVs in adult populations.
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